From contraindication to consideration: the role of esophagectomy in stage IV esophageal adenocarcinoma Authors: Agustina A Pontecorvo, Enrique F Elli Published: 2026 In this important contribution, Sewell and colleagues contribute to the ongoing discussion regarding the role of esophagectomy in selected patients with advanced esophageal adenocarcinoma (1). In the setting of increasingly effective systemic therapies, their work adds to a growing body of literature suggesting that esophagectomy may have a role within a carefully selected, multimodality treatment approach. Although the role of surgery in patients with metastatic disease who demonstrate response to systemic therapy remains controversial, this study appropriately advances the discussion surrounding patient selection and timing of intervention (2). The authors report encouraging perioperative and oncologic outcomes in a carefully selected cohort of patients with clinical stage IVB with metastatic disease, undergoing esophagectomy after a prolonged course of systemic therapy. Notably, the study demonstrates superior survival among patients with stage IVB disease who underwent esophagectomy compared with those managed without surgical resection. Importantly, this comparison is strengthened using propensity score-matched analysis, which enhances the validity of the findings by reducing selection bias and improving comparability between treatment groups. This methodological approach lends additional support to the central premise of the study, that appropriate patient selection, rather than stage alone, may be a critical determinant of outcomes, and provides compelling evidence that surgery can confer a survival advantage in carefully chosen metastatic patients. When performed at experienced, high-volume tertiary centers, perioperative morbidity and mortality were favorable (3). Collectively, these findings reinforce that salvage esophagectomy in stage IV disease should be restricted to specialized institutions and conducted within a rigorous multidisciplinary framework. In this context, surgery is best conceptualized as a targeted strategy for disease control, aimed at mitigating local progression, alleviating symptom burden, and preserving quality of life. One of the most provocative findings of the study is the observation that patients with stage IVA disease demonstrated inferior overall survival compared with those classified as stage IVB. Clinical tumor-node-metastasis staging is well recognized as a poor predictor of overall survival and limitations in the sensitivity of contemporary staging modalities may contribute to understaging among patients categorized as stage IVA, thereby obscuring more extensive locoregional or occult systemic disease (4-6). Moreover, patients with stage IVA disease frequently receive a relatively short course of neoadjuvant chemoradiation prior to surgery, potentially limiting adequate treatment of micrometastatic disease (7). In contrast, patients with stage IVB disease typically undergo prolonged systemic therapy, which may allow for more effective patient selection and systemic disease control before consideration of surgical intervention. We agree that the findings of this study challenge conventional, staging-driven treatment paradigms and suggest that select patients with stage IVA disease may benefit from a more prolonged course of neoadjuvant systemic therapy or chemoradiation prior to consideration of surgical resection. Such an approach could enhance systemic disease control, permit a more accurate assessment of tumor biology, and facilitate improved identification of patients most likely to derive meaningful benefit from surgery. The expanding role of immunotherapy further reinforces this argument. Immune checkpoint inhibitors, alone or in combination regimens, have demonstrated increasing efficacy in reducing disease burden and achieving durable responses in esophageal adenocarcinoma (8). These advances may be particularly consequential for patients with stage IVA disease, as well as those with initially unresectable stage IVA or IVB disease, by facilitating downstaging and potential conversion to surgical candidacy. Importantly, such an approach should remain limited to specialized centers and guided by rigorous multidisciplinary evaluation, with careful consideration of operative risk, anticipated oncologic benefit, and patient-centered outcomes (3). Beyond anatomic staging, an important conceptual consideration raised by this work is how best to define oligometastatic disease in clinical practice. The current study appears to rely primarily on anatomic distribution as an inclusion framework; however, emerging consensus suggests that anatomy alone may be insufficient to capture the biological heterogeneity of metastatic disease. In this context, criteria proposed by the Oligometastatic Esophagogastric Cancer (OMEC) consortium emphasize the integration of dynamic factors, such as response to systemic therapy and disease trajectory over time (9). Such parameters may more accurately reflect underlying tumor biology and help distinguish patients with indolent, treatment-responsive disease from those with more aggressive phenotypes unlikely to benefit from local intervention. Notably, the prolonged systemic therapy administered to the surgical cohort in this study may function as a surrogate marker of favorable biology, conceptually aligning with OMEC principles. Accordingly, future efforts to refine patient selection should aim to integrate anatomic, temporal, and biologic factors to more precisely define oligometastatic disease and guide therapeutic decision-making. Future directions The findings presented by Sewell and colleagues underscore the need for prospective studies aimed at refining patient selection and optimizing treatment sequencing in advanced esophageal adenocarcinoma (1). Prospective evaluation of prolonged neoadjuvant systemic therapy or chemoradiation in selected stage IVA patients may help clarify whether extended treatment can improve survival and better identify candidates for surgery. Equally important will be the continued integration of immunotherapy into multimodality treatment strategies. Defining the optimal timing, duration, and combination of immunotherapy with surgery represents a critical area for future research. In summary, while surgery in metastatic esophageal adenocarcinoma remains controversial and should not be broadly applied, this study supports a more nuanced, individualized approach. In the era of modern systemic therapy and immunotherapy, esophagectomy may offer meaningful oncologic and quality-of-life benefits for a highly selected subset of patients, provided it is performed in specialized centers and guided by thoughtful multidisciplinary decision-making. Supplementary The article’s supplementary files as Acknowledgments None. Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Footnotes Provenance and Peer Review: This article was commissioned by the editorial office, Journal of Thoracic Disease. The article has undergone external peer review. Funding: None. Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at https://jtd.amegroups.com/article/view/10.21037/jtd-2026-1-0330/coif). The authors have no conflicts of interest to declare. References Available at https://jtd.amegroups.com/article/view/10.21037/jtd-2026-1-0330/prf Supplementary Materials The article’s supplementary files as